Personal profile
About
Firas El Chaer, M.D., MSHCM, is a board-certified hematologist-oncologist and the chief of Leukemia and medical director of Infusion Services at Baptist Health Miami Cancer Institute. He specializes in the treatment of leukemia, with a primary focus on acute myeloid leukemia, acute lymphoblastic leukemia, chronic myelomonocytic leukemia and chronic myeloid leukemia. His expertise also extends to myeloproliferative neoplasms (primary myelofibrosis, essential thrombocytosis and polycythemia vera), clonal hematopoiesis of indeterminate potential as well as bone marrow failure disorders, including myelodysplastic syndromes and aplastic anemia.
Dr. El Chaer utilizes personalized, targeted therapies to enhance treatment effectiveness and improve patient responses. Additionally, he has a keen interest in measurable residual disease detection and monitoring, which can improve patients’ long-term outcomes and survival rates by catching early signs of relapse so treatments and adjusting treatments accordingly.
Related documents
Education/Academic qualification
Master of Science in Health Care Management
Award Date: May 1 2024
M.D., University Of Balamand, Beirut, Lebanon
Award Date: Jun 1 2011
B.S., Biology, University Of Balamand, Beirut, Lebanon
Award Date: Jun 1 2007
-
Advances and Controversies in the Management of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Navigating First-Line Therapies
Zahra, T., Bambace, N., Feinstein, L., El Chaer, C., Kadi, Y., Lezcano, M. A., Vega, Y., Al-Sagheer, T. & El Chaer, F., Dec 2026, In: Current Hematologic Malignancy Reports. 21, 1, 2.Research output: Contribution to journal › Review article › peer-review
-
Current treatments, practical management, and emerging investigational therapies for myelofibrosis
Tantravahi, S., El Chaer, F. & Bose, P., 2026, In: Expert Review of Hematology. 19, 3, p. 249-268 20 p.Research output: Contribution to journal › Review article › peer-review
-
Measurable residual mutated NPM1 before allogeneic transplant for acute myeloid leukemia
Al-Ali, R. W., Gui, G., Ravindra, N., Andrew, G., Mukherjee, D., Wong, Z. C., Huang, Y., Gerhold, J., Holman, M., Jacobsen, A., D’Angelo, J., Miller, J., Elias, K., Auletta, J. J., El Chaer, F., Devine, S. M., Jimenez, A. M. J., De Lima, M. J. G., Litzow, M. R. & Kebriaei, P. & 8 others, , Feb 2026, In: Bone Marrow Transplantation. 61, 2, p. 222-224 3 p.Research output: Contribution to journal › Letter › peer-review
Open Access -
The global epidemiology of acute myeloid leukaemia
El Chaer, F., Bewersdorf, J. P., Stahl, M. & Zeidan, A. M., Feb 2026, In: Nature Reviews Clinical Oncology. 23, 2, p. 107-120 14 p.Research output: Contribution to journal › Review article › peer-review
-
American Society for Transplantation and Cellular Therapy Series #10: Management of Parainfluenza and Human Metapneumovirus Infections in Hematopoietic Cell Transplantation and Cellular Therapy Recipients
Batista, M. V., El Chaer, F., Englund, J. A., Boeckh, M., Carpenter, P. A., Dadwal, S. S., Waghmare, A., Navarro, D., Hirsch, H. H., Piñana, J. L., Papanicolaou, G. A. & Chemaly, R. F., Sep 2025, In: Transplantation and cellular therapy. 31, 9, p. 624-638 15 p.Research output: Contribution to journal › Article › peer-review
-
MRD testing prior to alloSCT can predict OS and DFS in AML
El Chaer, F. (Member)
Jun 18 2024Activity: Other
-
Pre-Allogeneic Transplantation Flow Cytometry Testing for Patients with AML in First CR, as Currently Performed, Has Limited Clinical Utility for Relapse and Survival Prediction: a CIBMTR Analysis
El Chaer, F. (Speaker) & Additional Authors and Affiliations (Speaker)
2024Activity: Talk or presentation › Oral presentation
-
Measurable Residual IDH2 before Allogeneic Transplant for Acute Myeloid Leukemia
El Chaer, F. (Speaker) & Additional Authors and Affiliations (Speaker)
2023Activity: Talk or presentation › Oral presentation
-
Phase 1/2 Study of TP-3654, a Selective PIM1 Kinase Inhibitor: Preliminary Data Showed Clinical Activity and Cytokine Reductions in Relapsed/Refractory Myelofibrosis Patients
El Chaer, F. (Speaker) & Additional Authors and Affiliations (Speaker)
2023Activity: Talk or presentation › Oral presentation
-
The role of post-transplant maintenance therapy in AML
El Chaer, F. (Member)
Apr 25 2022Activity: Other